Propofol for Sedation of Postoperative Electively Ventilated Liver Transplant Recipients.

Last updated: February 6, 2019
Sponsor: Institute of Liver and Biliary Sciences, India
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hepatic Fibrosis

Hyponatremia

Treatment

N/A

Clinical Study ID

NCT03837145
ILBS-TRANSPLANT ANESTHESIA-01
  • Ages 18-70
  • All Genders

Study Summary

All consenting, adult patients aged 18 years and above who will require elective ventilation after liver transplant recipient surgery will be enrolled for the study. Patients in acute liver failure, hepatic encephalopathy or patients with history of allergic reactions to propofol will be excluded from the study. This is an observational study. As per institute treatment protocol, propofol will be given post-operatively at a dose of 1 mg/kg/hr and than titrated to maintain a Bi-Spectral Index (BIS) score of 60-80 till the patient is on ventilator. There will be no deviation from our routine institutional protocol and no other sedative drugs like opioids or benzodiazepines will be used and no interventions will be done. Hemodynamics will be maintained targeting a mean arterial pressure (MAP) of at least 65 mm Hg. during the study period using appropriate measures.

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Living donor liver transplant (LDLT) recipient adult patients ≥ 18 years of age requiringpostoperative elective ventilation.

Exclusion

Exclusion Criteria:

  • Propofol allergy

  • Acute liver failure (ALF).

  • Hepatic encephalopathy (HE)

Study Design

Total Participants: 30
Study Start date:
January 12, 2019
Estimated Completion Date:
March 31, 2019

Connect with a study center

  • Institute of liver and biliary sciences

    New Delhi, Delhi 110070
    India

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.